To further validate the role of ADAMTS8 clinically, the survival analyses from KM plotter revealed a longer overall survival time (OS) and time to first progression (FP) but not post-progression survival (PPS) in lung cancer patients with high ADAMTS8 expression. Here, ADAMTS8 is linked to lung cancer.